Li-Ying, JasonJohn Wiley & Sons, Ltd.R & D ManagementBuonansegna, E., Salomo, S., Maier, A. M., and Li-Ying, J., 2014, "Pharmaceutical New Product Development: Why do Clinical Trials Fail?," R&D Manage., 44(2), pp. 189-202....
Patient involvement in clinical research: why, when, and how. Patient Prefer Adherence. 2016;10:631. Article PubMed PubMed Central Google Scholar Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials. 2017;18:1–7. Article ...
Opal S M. Clinical trials of novel therapeutic agents: why did they fail? In: Vincent J L, editor. Yearbook of intensive care and emergency medicine. Berlin, Germany: Springer-Verlag; 1995. pp. 425–436.Opal SM. Clinical trials of novel therapeutic agents: why did they fail? In: ...
Murphy E,Allen DG.Why did the NHE inhibitor clinical trials fail?. Journal of Molecular and Cellular Cardiology . 2009Murphy E, Allen DG: Why did the... E Murphy,DG Allen - 《Journal of Molecular & Cellular Cardiology》 被引量: 90发表: 2009年 Why did the NHE inhibitor clinical trials ...
Multiple drugs have been evaluated for the treatment of NAFLD. Why do most agents fail to progress from phase 2 to phase 3 trials? Or from phase 3 to approval? There are several reasons why some of these drugs had to be stopped during clinical development. Obviously, a lot were stopped ...
will fail in clinical trials with real patients. 将会在临床试验真正的病人时失败 One of the complexities of aggressive tumors 侵略性肿瘤的复杂性之一 is that they can have multiple populations of slightly different cancerous cells. 是它们有多种略有不同的癌细胞 ...
4. AI monitors participant adherence in clinical trials Medication non-adherence is rather common. Studies indicate that50% of Americans fail to taketheir long-term chronic medication as instructed. And according to the World Health Organization, medication adherence can have an even bigger...
However, nine out of ten drug candidates after they have entered clinical studies would fail during phase I, II, III clinical trials and drug approval2,3. It is also worth noting that the 90% failure rate is for the drug candidates that are already advanced to phase I clinical trial, ...
Random- ized clinical trials have demonstrated that statins reduces CRP, multiple cytokines, and inflammatory markers in the body. Even with modest anti-inflammatory properties, statins do not appear to enhance insulin resistance or significantly improve glycemia[70]. A recent review published in JAMA...
Numerous pre-clinical models, both small and large, exist but do not easily translate into clinical studies. This is likely in part due to an overall adherence to the directions provided by the regulatory agencies that, up to 2014, was calculated as below 60% [6]. Reparative and restorative...